Key facts
- AN2 Therapeutics announced positive clinical trial results for its Chagas disease treatment.
- The study demonstrated the drug's efficacy in patients with the infectious disease.
- The therapy is codenamed AN2-345.
- The therapy showed promising results in preclinical studies.
AN2 Therapeutics Inc. announced positive early-stage trial data for its Chagas disease therapy. The therapy, codenamed AN2-345, showed promising results in preclinical studies. The study demonstrated the drug's efficacy in patients with the infectious disease.